Analysts expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to report $4.38 billion in sales for the current quarter, Zacks reports. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings, with the lowest sales estimate coming in at $4.29 billion and the highest estimate coming in at $4.42 billion. Teva Pharmaceutical Industries posted sales of $4.56 billion in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.9%. The firm is expected to report its next earnings results on Wednesday, February 12th.
According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year sales of $17.28 billion for the current fiscal year, with estimates ranging from $17.19 billion to $17.32 billion. For the next year, analysts expect that the business will post sales of $17.08 billion, with estimates ranging from $16.59 billion to $17.75 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, November 7th. The company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. The business had revenue of $4.26 billion during the quarter, compared to analysts’ expectations of $4.25 billion.
Several research firms have commented on TEVA. ValuEngine lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 3rd. Gabelli upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Wells Fargo & Co decreased their target price on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating on the stock in a research report on Monday, September 30th. Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They set a “neutral” rating on the stock. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 price target for the company in a report on Tuesday, November 12th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $10.64.
In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 4,310 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.49, for a total transaction of $45,211.90. Following the completion of the transaction, the vice president now owns 24,883 shares in the company, valued at $261,022.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.49% of the company’s stock.
A number of institutional investors have recently made changes to their positions in TEVA. Nomura Asset Management Co. Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 16.9% during the second quarter. Nomura Asset Management Co. Ltd. now owns 319,862 shares of the company’s stock worth $2,952,000 after purchasing an additional 46,200 shares during the last quarter. Natixis grew its holdings in shares of Teva Pharmaceutical Industries by 245.0% in the second quarter. Natixis now owns 235,274 shares of the company’s stock worth $2,172,000 after purchasing an additional 167,083 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec increased its stake in Teva Pharmaceutical Industries by 1.0% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 815,921 shares of the company’s stock worth $7,531,000 after buying an additional 8,235 shares during the period. Canada Pension Plan Investment Board purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $6,893,000. Finally, CIBC Asset Management Inc increased its stake in Teva Pharmaceutical Industries by 6.6% in the 3rd quarter. CIBC Asset Management Inc now owns 66,513 shares of the company’s stock worth $458,000 after buying an additional 4,128 shares during the period. 53.53% of the stock is currently owned by institutional investors.
Teva Pharmaceutical Industries stock opened at $10.12 on Friday. The company has a market cap of $10.89 billion, a price-to-earnings ratio of 3.61, a PEG ratio of 1.07 and a beta of 1.83. The firm’s fifty day moving average is $9.73 and its 200 day moving average is $8.29. The company has a quick ratio of 0.56, a current ratio of 0.89 and a debt-to-equity ratio of 1.62. Teva Pharmaceutical Industries has a 52-week low of $6.07 and a 52-week high of $20.21.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Limitations of the P/E Growth ratio
Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.
